West Pharmaceutical Services posts strong Q3 2026 results and lifts full‑year outlook
+1 new source since this summary was written
West Pharmaceutical Services reported third‑quarter 2026 net sales of $874.5 million, up 8.7% year‑over‑year, and adjusted diluted earnings per share of $2.66, up 35.7%. The company raised its full‑year 2026 net‑sales guidance to $3.41‑$3.42 billion and adjusted‑diluted EPS guidance to $9.38‑$9.48. Management highlighted double‑digit organic growth in high‑value product components and a 310‑basis‑point expansion in gross margin.
Why it matters
The higher guidance suggests stronger revenue and earnings expectations for the rest of 2026, which could support the stock price and affect analysts' target models. The margin expansion indicates improved profitability, potentially increasing cash flow for share repurchases and dividend growth.
Key facts
- 1Third‑quarter 2026 net sales were $874.5 million, an 8.7% increase from the prior year. sec.gov
- 2Adjusted diluted EPS for the quarter was $2.66, a 35.7% rise year‑over‑year. sec.gov
- 3Full‑year 2026 net‑sales guidance was raised to a range of $3.41 billion‑$3.42 billion. sec.gov
- 4Full‑year 2026 adjusted‑diluted EPS guidance was raised to $9.38‑$9.48. sec.gov
- 5Gross margin expanded 310 basis points year‑over‑year to 39.7%. investing.com
- 6Operating margin increased 420 basis points year‑over‑year to 25.3%. investing.com
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.